Cousin François, Louis Thomas, Frères Pierre, Guiot Julien, Occhipinti Mariaelena, Bottari Fabio, Vos Wim, Hustinx Roland
Department of Nuclear Medicine and Oncological Imaging, University Hospital (CHU) of Liège, Liège, Belgium.
Radiomics (Oncoradiomics SA), Liège, Belgium.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251344004. doi: 10.1177/15330338251344004. Epub 2025 May 23.
ObjectiveCheckpoint inhibitor pneumonitis (CIP) is a potentially life-threatening immune-related adverse event. Efficient strategies to select patients at risk are still required. The aim of our study was to assess the utility of a machine learning model, integrating pre-treatment CT lung radiomics features with clinical data, to predict patients at risk of developing CIP.MethodsIn this retrospective study, 116 patients with varied malignancies treated with immune checkpoint inhibitors (ICIs) were included. In this cohort, 35 patients presented with CIP and 81 patients did not. Each lung and its lobes were segmented on pre-treatment CT scans to perform a handcrafted radiomic analysis. Radiomic features were associated with clinical parameters to build generalized linear (GLM) and random forest (RF) models, to predict occurrence of CIP. The models were fine-tuned, validated and tested using a nested 5-fold cross-validation method.ResultsThe RF models combining radiomic and clinical features showed the best performances with an area under the ROC curve (AUC) of 0.75 (95%CI:0.62-0.88) on the test set. The most accurate clinical model was a RF model and achieved an AUC of 0.72 (95%CI:0.51-0.92). The best radiomic model was a GLM model and achieved an AUC of 0.71 (95%CI:0.58-0.84).ConclusionsOur CT-based lung radiomic models showed moderate to good performance at predicting CIP. We demonstrated the potential role of machine learning models associating clinical parameters and lung CT radiomic features to better identify patients treated with ICIs at risk of developing CIP.Advances in knowledge: Radiomics analysis of the lung parenchyma could be used as a non-invasive tool to select patients at risk of developing immune-checkpoint pneumonitis.
目的
检查点抑制剂肺炎(CIP)是一种潜在的危及生命的免疫相关不良事件。仍需要有效的策略来筛选有风险的患者。我们研究的目的是评估一种机器学习模型的效用,该模型将治疗前CT肺部影像组学特征与临床数据相结合,以预测发生CIP的风险患者。
方法
在这项回顾性研究中,纳入了116例接受免疫检查点抑制剂(ICI)治疗的不同恶性肿瘤患者。在这个队列中,35例患者出现CIP,81例患者未出现。在治疗前的CT扫描上对每个肺及其肺叶进行分割,以进行手工影像组学分析。将影像组学特征与临床参数相关联,建立广义线性(GLM)和随机森林(RF)模型,以预测CIP的发生。使用嵌套的5折交叉验证方法对模型进行微调、验证和测试。
结果
结合影像组学和临床特征的RF模型表现最佳,在测试集上的受试者工作特征曲线下面积(AUC)为0.75(95%CI:0.62 - 0.88)。最准确的临床模型是RF模型,AUC为0.72(95%CI:0.51 - 0.92)。最佳的影像组学模型是GLM模型,AUC为0.71(95%CI:0.58 - 0.84)。
结论
我们基于CT的肺部影像组学模型在预测CIP方面表现出中等至良好的性能。我们证明了将临床参数与肺部CT影像组学特征相关联的机器学习模型在更好地识别接受ICI治疗有发生CIP风险的患者方面的潜在作用。
肺实质的影像组学分析可作为一种非侵入性工具来筛选有发生免疫检查点肺炎风险的患者。